bio-convergence Israel EU

bio-convergence - 
connecting the innovation systems of the 
European Union and the State of Israel

The European Investment Bank and the Israel Innovation Authority  have concluded a cooperation agreement to jointly pursue investments in the globally emerging domain of bio-convergence . The collaboration's aim is to advance the technological and investment alliances particularly at the intersection of biopharma, information technology and engineering. These four industries are pillars of both European and Israeli R&I systems, and they are indispensable components towards achieving both partner's global public health goals. 
 
Through the co-investment scheme, the European Investment Bank and the Israel Innovation Authority expect to invest equal amounts pari passu into individual companies. Investments will be made as non-dilutive venture debt, according to each investor’s rules and regulations. The cooperation is governed by a Memorandum of Understanding signed on April 30, 2020, and has an initial investment term of two years.

If you represent a company and interested to benefit from this scheme, please contact info@kenup.eu, or get directly in touch with the European Investment Bank or the Israel Innovation Authority, 

the signing ceremony

During an Online Ceremony held on April 30, 2020, the European Investment Bank and the Israel Innovation Authority signed the cooperation agreement  to jointly pursue investments in the domain of bio-convergence.  Initiating this cooperation,  a Financing Agreement between Pluristem Therapeutics Inc. and the European Investment Bank has been executed directly thereafter.  The European Commission has published a web notification as well as a press release on the matter. 
Share by: